Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.35 |
| ▸ | PSMB2 | P49721 | 5/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.35 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10198897 | 0.87 | SSTR3 (0.44) | SIRT2SIRT1HDAC1PSMB1PSMB5 | |
| SCHEMBL22698598 | 0.82 | HDAC8 (0.51) | SIRT5SIRT2SIRT1HDAC1SIRT3 | |
| SCHEMBL12836356 | 0.81 | FOLH1 (0.42) | — | |
| SCHEMBL20143906 | 0.79 | HDAC8 (0.39) | SIRT5SIRT2SIRT1HDAC1SIRT3 | |
| SCHEMBL15704359 | 0.78 | HDAC8 (0.46) | SIRT2SIRT1HDAC1PSMB5SIRT3 | |
| SCHEMBL12435181 | 0.78 | FOLH1 (0.44) | — | |
| SCHEMBL16847583 | 0.76 | HDAC8 (0.55) | SIRT5SIRT2SIRT1HDAC1SIRT3 | |
| SCHEMBL29649540 | 0.76 | FOLH1 (0.45) | — | |
| SCHEMBL16266210 | 0.76 | SSTR3 (0.44) | PSMB1PSMB5PSMB2CTSL | |
| SCHEMBL13893442 | 0.76 | FAP (0.45) | SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110064753-A1 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-7829531-B2 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | SEATTLE GENETICS INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7659241-B2 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090324621-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064753-A1 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | CD47, CD2, CD22 | SIRT5 2032/4885SIRT2 3033/4885SIRT1 2283/4885 |
| US-20090324621-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | DAD1, DDOST, STT3A | SIRT5 999/4885SIRT2 2395/4885SIRT1 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.